The results revealed that colorectal cancer patients with high ASB6 expression were less sensitive to anti-PD-L1 immunotherapy, with a predictive AUC value of 0.669 (p = 0.032) (Figure 7F, G). This evidence concerns the gene ASB6 and colorectal cancer.